Evidence map›Paper›PMID 25604651›Full record

ReviewCurrent urology reports2015

Renal cell carcinoma in young patients: a review of recent literature.

Michael Daugherty, Gennady Bratslavsky

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael DaughertyDepartment of Urology, SUNY Upstate Medical University, Syracuse, NY, 13306, USA.
Gennady Bratslavsky

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma is most common in patients in the seventh decade of life. However, renal cell carcinoma (RCC) patients under the age of 40 represent 3-7% of all renal tumors. These young patients develop RCC from a variety of mechanisms including genetic syndromes, heritable mutations, and sporadic mutations. This population encompasses a distinct clinical entity that requires early identification and adjustments in standard practices including sometimes-aggressive surgical measures in order to improve oncologic management.

Indexed as

Age FactorsCarcinoma, Renal CellGlobal HealthHumansIncidenceKidney NeoplasmsYoung Adult

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.